Skip to content
This site uses cookies to provide you with a better browsing experience. More information can be found on the IgGenix
Privacy Policy page.
Accept
Abstracts
- Croote, D. et. al, “Preclinical Activity and GLP Safety Toxicology Data Ahead of Phase 1 Initiation of IGNX001 in Peanut Allergy” Presented at 2024 ASCIA Annual Conference
- Croote, D. et. al, “IGNX001 Inhibits Peanut-Mediated Mast Cell Activation in a Translational Spike-In Assay” Presented at 2024 EAACI Annual Meeting
- Croote, D. et al, “Discovery of Monoclonal IgE Autoantibodies from Atopic Dermatitis Patients” Presented at 2024 EAACI Annual Meeting
- Croote, D. et al, “IGNX001 Abrogates Peanut-mediated Mast Cell Degranulation and Murine Anaphylaxis” Presented at 2024 AAAAI Annual Meeting
- Hamilton, R.G. et al, “Cat Pelt/Hair Extract US Potency: Updating the Predicate Fel d 1 RID with a mAb-based ELISA ” Presented at 2024 AAAAI Annual Meeting
- Thomas, R. et al, “IgGenix Antibodies Enable Less Frequent Administration and Rapid Protection Against Accidental Exposure, Addressing the Challenges of OIT in Peanut Allergy” Presented at FOCIS 2023 Annual Meeting
- Croote, D. et al, “Treating Peanut Allergy with an IgG4 Monoclonal Antibody-based Approach” Presented at EAACI 2023 Congress
- Croote, D. et al, “Deconstructing the Human IgE Response in Peanut Allergy” Presented at WAO 2023 Symposium
- Chung, CP.B, et al, “Cross-Reactive Shellfish-Specific Monoclonal IgE Antibodies Discovered from Highly Allergic Individuals” Presented at AAAAI 2023 Annual Meeting
BACK